AbbVie's oral JAK inhibitor Rinvoq may be stuck in something of a regulatory holding pattern in the US, but in Europe has been recommended for approval as a treatment for atopic dermatitis (AD).
Our latest Physician Views poll seeks further clarity from dermatologists as to how they might use Rinvoq and what competition it could pose to Sanofi and Regeneron Pharmaceuticals' Dupixent in the AD market.
We are asking European dermatologists…
Survey results and analysis will be published later this week for FirstWord Pharma PLUS subscribers and can be purchased by non-FirstWord Pharma PLUS subscribers. To be notified when they become available, click here
To read more Physician Views articles, click here.